$34.24
-0.61-1.75%
At close: -
$34.50
0.260.76%
After Hours: 7:41 PM EDT
Comments
Loading...
BridgeBio Pharma Analyst Ratings and Price Targets | NASDAQ:BBIO | Benzinga
BridgeBio Pharma Inc has a consensus price target of $46.74 based on the ratings of 21 analysts. The high is $95 issued by Cantor Fitzgerald on February 21, 2025. The low is $19 issued by SVB Leerink on January 23, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Redburn Atlantic, and JP Morgan on April 15, 2025, March 31, 2025, and March 24, 2025, respectively. With an average price target of $51 between HC Wainwright & Co., Redburn Atlantic, and JP Morgan, there's an implied 47.83% upside for BridgeBio Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Redburn Atlantic
JP Morgan
Citigroup
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for BridgeBio Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | Buy Now | 53.62% | HC Wainwright & Co. | Raghuram Selvaraju41% | $49 → $53 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 44.93% | Redburn Atlantic | Joshua Smith 14% | → $50 | Initiates | → Buy | Get Alert |
| 03/24/2025 | Buy Now | 44.93% | JP Morgan | Anupam Rama58% | $44 → $50 | Maintains | Overweight | Get Alert |
| 02/21/2025 | Buy Now | 42.03% | Citigroup | David Lebowitz52% | $45 → $49 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 175.36% | Cantor Fitzgerald | Josh Schimmer51% | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
| 02/21/2025 | Buy Now | 50.72% | Scotiabank | Greg Harrison40% | $49 → $52 | Maintains | Sector Outperform | Get Alert |
| 02/13/2025 | Buy Now | 42.03% | HC Wainwright & Co. | Raghuram Selvaraju41% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 42.03% | Scotiabank | Greg Harrison40% | $48 → $49 | Maintains | Sector Outperform | Get Alert |
| 12/23/2024 | Buy Now | 44.93% | Evercore ISI Group | Cory Kasimov67% | $45 → $50 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | 42.03% | HC Wainwright & Co. | Raghuram Selvaraju41% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 39.13% | Scotiabank | Greg Harrison40% | $45 → $48 | Maintains | Sector Outperform | Get Alert |
| 11/25/2024 | Buy Now | 30.43% | B of A Securities | Geoff Meacham60% | $42 → $45 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 42.03% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $49 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 30.43% | Scotiabank | Greg Harrison40% | $44 → $45 | Maintains | Sector Outperform | Get Alert |
| 10/25/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 33.33% | Leerink Partners | Mani Foroohar48% | $47 → $46 | Maintains | Outperform | Get Alert |
| 10/16/2024 | Buy Now | 27.54% | Scotiabank | Greg Harrison40% | → $44 | Initiates | → Sector Outperform | Get Alert |
| 10/03/2024 | Buy Now | — | Oppenheimer | Leland Gershell68% | — | Initiates | → Perform | Get Alert |
| 10/02/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/30/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 102.9% | Cantor Fitzgerald | Josh Schimmer51% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 21.74% | B of A Securities | Geoff Meacham60% | $42 → $42 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 102.9% | Cantor Fitzgerald | Josh Schimmer51% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 33.33% | Piper Sandler | Biren Amin39% | → $46 | Initiates | → Overweight | Get Alert |
| 09/03/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/27/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 24.64% | JP Morgan | Anupam Rama58% | $46 → $43 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 30.43% | Evercore ISI Group | Cory Kasimov67% | $50 → $45 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 102.9% | Cantor Fitzgerald | Josh Schimmer51% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 06/25/2024 | Buy Now | 21.74% | B of A Securities | Geoff Meacham60% | $50 → $42 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 102.9% | Cantor Fitzgerald | Josh Schimmer51% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 05/28/2024 | Buy Now | 36.23% | UBS | Eliana Merle42% | $51 → $47 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 24.64% | HC Wainwright & Co. | Raghuram Selvaraju41% | $47 → $43 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 44.93% | Evercore ISI Group | Cory Kasimov67% | → $50 | Initiates | → Outperform | Get Alert |
| 03/20/2024 | Buy Now | 30.43% | JP Morgan | Anupam Rama58% | $35 → $45 | Maintains | Overweight | Get Alert |
| 03/19/2024 | Buy Now | 102.9% | Cantor Fitzgerald | Josh Schimmer51% | $60 → $70 | Maintains | Overweight | Get Alert |
| 03/11/2024 | Buy Now | 73.91% | Cantor Fitzgerald | Josh Schimmer51% | $50 → $60 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 53.62% | Mizuho | Salim Syed42% | $60 → $53 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 36.23% | HC Wainwright & Co. | Raghuram Selvaraju41% | $47 → $47 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 33.33% | Citigroup | David Lebowitz52% | $42 → $46 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 7.25% | BMO Capital | Kostas Biliouris32% | → $37 | Initiates | → Market Perform | Get Alert |
| 01/29/2024 | Buy Now | 36.23% | HC Wainwright & Co. | Raghuram Selvaraju41% | $22 → $47 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 44.93% | Cantor Fitzgerald | Josh Schimmer51% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 21.74% | Citigroup | David Lebowitz52% | → $42 | Initiates | → Buy | Get Alert |
| 10/24/2023 | Buy Now | 44.93% | Cantor Fitzgerald | Josh Schimmer51% | → $50 | Initiates | → Overweight | Get Alert |
| 08/28/2023 | Buy Now | 73.91% | Mizuho | Salim Syed42% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | 10.14% | JP Morgan | Anupam Rama58% | $42 → $38 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 73.91% | Mizuho | Salim Syed42% | $50 → $60 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 44.93% | Goldman Sachs | Paul Choi60% | $29 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 33.33% | Raymond James | Dane Leone47% | $29 → $46 | Maintains | Outperform | Get Alert |
| 07/18/2023 | Buy Now | -4.35% | Jefferies | Eun Yang34% | $24 → $33 | Downgrade | Buy → Hold | Get Alert |
| 05/08/2023 | Buy Now | -15.94% | Mizuho | Salim Syed42% | $23 → $29 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 15.94% | Evercore ISI Group | Josh Schimmer51% | → $40 | Initiates | → Outperform | Get Alert |
| 04/13/2023 | Buy Now | -21.74% | SVB Securities | Mani Foroohar48% | $25 → $27 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | -33.33% | JP Morgan | Anupam Rama58% | $18 → $23 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | -18.84% | Goldman Sachs | Paul Choi60% | $20 → $28 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | -15.94% | Raymond James | Dane Leone47% | $17 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren44% | — | Initiates | → Outperform | Get Alert |
| 01/23/2023 | Buy Now | -44.93% | SVB Leerink | Mani Foroohar48% | $23 → $19 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | -44.93% | JP Morgan | Anupam Rama58% | $20 → $19 | Maintains | Overweight | Get Alert |
| 08/24/2022 | Buy Now | -33.33% | Mizuho | Salim Syed42% | $25 → $23 | Maintains | Buy | Get Alert |
| 07/26/2022 | Buy Now | -13.04% | SVB Leerink | Mani Foroohar48% | $27 → $30 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -44.93% | Goldman Sachs | Paul Choi60% | $24 → $19 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | -21.74% | SVB Leerink | Mani Foroohar48% | $26 → $27 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for BridgeBio Pharma (BBIO) stock?
The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by HC Wainwright & Co. on April 15, 2025. The analyst firm set a price target for $53.00 expecting BBIO to rise to within 12 months (a possible 53.62% upside). 41 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by HC Wainwright & Co., and BridgeBio Pharma maintained their buy rating.
When was the last upgrade for BridgeBio Pharma (BBIO)?
There is no last upgrade for BridgeBio Pharma
When was the last downgrade for BridgeBio Pharma (BBIO)?
The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $49.00 to $53.00. The current price BridgeBio Pharma (BBIO) is trading at is $34.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.